Brokerages Set Twist Bioscience Co. (NASDAQ:TWST) Price Target at $48.22

Twist Bioscience Co. (NASDAQ:TWST) has been given an average rating of “Moderate Buy” by the nine analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $48.22.

Several brokerages have commented on TWST. The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Evercore ISI increased their price objective on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Barclays dropped their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Robert W. Baird upped their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Finally, Scotiabank lifted their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday, May 6th.

Insider Activity

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the business’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total transaction of $47,120.94. Following the transaction, the senior vice president now owns 90,593 shares of the company’s stock, valued at $4,650,138.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Patrick John Finn sold 2,207 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total transaction of $124,960.34. Following the sale, the chief operating officer now owns 171,212 shares of the company’s stock, valued at approximately $9,694,023.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Paula Green sold 918 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total value of $47,120.94. Following the completion of the transaction, the senior vice president now owns 90,593 shares of the company’s stock, valued at $4,650,138.69. The disclosure for this sale can be found here. Insiders sold 21,327 shares of company stock worth $978,760 over the last ninety days. Corporate insiders own 3.92% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently modified their holdings of the business. Capital Impact Advisors LLC raised its holdings in Twist Bioscience by 16.1% in the 2nd quarter. Capital Impact Advisors LLC now owns 20,380 shares of the company’s stock valued at $1,004,000 after buying an additional 2,821 shares during the period. Algert Global LLC lifted its holdings in shares of Twist Bioscience by 114.8% in the 2nd quarter. Algert Global LLC now owns 27,300 shares of the company’s stock worth $1,345,000 after acquiring an additional 14,590 shares during the last quarter. Driehaus Capital Management LLC boosted its position in shares of Twist Bioscience by 63.0% during the 2nd quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock worth $19,152,000 after purchasing an additional 150,260 shares during the period. Scientech Research LLC increased its holdings in Twist Bioscience by 102.7% in the 2nd quarter. Scientech Research LLC now owns 31,435 shares of the company’s stock valued at $1,549,000 after purchasing an additional 15,924 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Twist Bioscience by 3.7% in the second quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company’s stock valued at $1,531,000 after purchasing an additional 1,104 shares during the period.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $43.56 on Friday. The company has a 50 day moving average price of $50.35 and a 200-day moving average price of $42.06. Twist Bioscience has a 1-year low of $14.42 and a 1-year high of $60.90. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -12.96 and a beta of 1.80.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The firm had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. During the same period in the previous year, the firm posted ($1.01) EPS. The firm’s quarterly revenue was up 27.7% on a year-over-year basis. On average, sell-side analysts anticipate that Twist Bioscience will post -3.13 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.